CRISPR | CHOP Research Institute


Published on
Jun 20, 2024
Using CRISPR/Cas9 gene editing in an early-stage clinical trial, researchers showed improved vision for a severe inherited form of blindness.
Published on
Apr 10, 2024
Evan Weber, PhD, and a research team from CHOP and Stanford Medicine discovered that the protein FOXO1 plays a key role in regulating CAR T cells’ longevity and effectiveness.
Published on
Feb 28, 2024
William Peranteau, MD, along with CHOP and Penn researchers are developing “one-and-done” new base-editing therapies for three genetic diseases of newborns.
Published on
Jan 3, 2024
After decades of limited progress in treating sickle cell disease, we have reached an historical moment with two new gene therapies.
Published on
Nov 10, 2023
This week’s research news features awards for furthering patient-centered outcomes research careers and for recognizing the importance of mentorship.
Published on
Feb 3, 2023
In this news roundup, we celebrate research tools new and old, from RNA sequencing to gene editing to the best tool of all: collaboration.
Published on
Jun 24, 2022
This week’s In the News features endocrinology research, news on gene therapy in blood disorders, CAR T-cell therapy, and more.
Published on
Dec 20, 2021
Dr. Carpenter’s research seeks to better understand how environmental factors affect the origins of disease via epigenetic modifications.

Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.

bailisw [at]
Published on
May 24, 2021
A previously unreported immunodeficiency disease prevents the formation of the B cells and antibodies that help fight off infections.